{"id":660312,"date":"2026-10-12T09:18:46","date_gmt":"2026-10-12T07:18:46","guid":{"rendered":"https:\/\/preprod.aivancity.ai\/blog\/pink-october-2026-what-ai-really-changes-in-breast-cancer-screening\/"},"modified":"2026-10-16T12:39:35","modified_gmt":"2026-10-16T10:39:35","slug":"pink-october-2026-what-ai-really-changes-in-breast-cancer-screening","status":"publish","type":"post","link":"https:\/\/preprod.aivancity.ai\/blog\/en\/pink-october-2026-what-ai-really-changes-in-breast-cancer-screening\/","title":{"rendered":"Pink October 2026: what AI really changes in breast cancer screening"},"content":{"rendered":"\n
\n

\n I<\/span>n 2026<\/strong>, several\n clinical studies<\/strong> evaluated\n artificial intelligence in breast cancer screening<\/strong>,\n going beyond retrospective testing alone.\n The randomized\n MASAI<\/strong>\n trial reports fewer\n cancers detected between two screening rounds<\/strong>,\n while other studies show\n possible gains in detection and reading workload<\/strong>.\n These results mark an important milestone,\n without demonstrating that AI can\n replace radiologists or that it is already improving mortality.<\/strong>\n <\/p>\n<\/div>\n\n

\n\n
\n 01\n <\/div>\n\n

\nIn 2026, AI faces the test of real-world screening\n <\/h2>\n\n<\/div>\n\n

Breast cancer remains a major global challenge. The World Health Organization estimates that 2.4 million women were diagnosed in 2024 and that the disease caused around 694,000 deaths.[1]<\/a><\/sup> For Pink October 2026, the central question is now whether AI improves a real-world screening program without creating new risks.<\/p>\n\n

The 2026 publications provide more robust evidence than isolated performance figures. In Sweden, the MASAI trial compared AI-supported screening with standard double reading in more than 100,000 participants. In the United Kingdom and Spain, other studies tested AI as a second reader, a triage tool, or a system that rules out exams deemed to be at very low risk.[3]<\/a>[4]<\/a>[5]<\/a>[6]<\/a><\/sup><\/p>\n\n

In France, the organizational context is decisive. The national program invites women aged 50 to 74 to have a mammogram every two years and provides for a second reading of exams judged normal on the first reading. Yet standardized participation reached only 45.7% in 2024\u20132025, compared with 46.6% in 2022\u20132023.[2]<\/a><\/sup> Better image reading therefore does not solve access delays, territorial inequalities, or women forgoing screening.<\/p>\n\n

\n\n
\n 02\n <\/div>\n\n

\nWhat is truly new in the 2026 results\n <\/h2>\n\n<\/div>\n\n

MASAI\u2019s most important contribution concerns interval cancers, which are diagnosed after a mammogram considered negative and before the next screening. The observed rate was 1.55 per 1,000 in the AI-supported group, compared with 1.76 per 1,000 with conventional double reading. This corresponds to a relative difference of 12%.[3]<\/a><\/sup><\/p>\n\n

This finding is clinically more informative than a simple accuracy score on archived images. It suggests that an AI-supported workflow can detect earlier some cancers that would otherwise have emerged between two screening rounds. Caution is still warranted, however: the trial established non-inferiority on this endpoint, but its confidence interval does not allow a firm conclusion of statistical superiority.<\/p>\n\n

The studies also compare complete workflows. GEMINI modeled 17 configurations on 10,889 women. A strategy adding human review of AI alerts identified 11 additional cancers. Gains and constraints therefore vary with the chosen organization.[5]<\/a><\/sup><\/p>\n\n